WO1999063081A2 - Ion channels - Google Patents
Ion channels Download PDFInfo
- Publication number
- WO1999063081A2 WO1999063081A2 PCT/GB1999/001743 GB9901743W WO9963081A2 WO 1999063081 A2 WO1999063081 A2 WO 1999063081A2 GB 9901743 W GB9901743 W GB 9901743W WO 9963081 A2 WO9963081 A2 WO 9963081A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- nucleic acid
- protein
- cell
- spasic
- seq
- Prior art date
Links
- 102000004310 Ion Channels Human genes 0.000 title claims abstract description 24
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 88
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 84
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 84
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 68
- 101100163907 Rattus norvegicus Asic4 gene Proteins 0.000 claims abstract description 55
- 238000000034 method Methods 0.000 claims abstract description 55
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 43
- 239000013598 vector Substances 0.000 claims abstract description 36
- 239000012634 fragment Substances 0.000 claims abstract description 29
- 108090000862 Ion Channels Proteins 0.000 claims abstract description 23
- 230000000694 effects Effects 0.000 claims abstract description 23
- 238000012216 screening Methods 0.000 claims abstract description 16
- 239000000126 substance Substances 0.000 claims abstract description 11
- 108091005462 Cation channels Proteins 0.000 claims abstract description 10
- 239000002253 acid Substances 0.000 claims abstract description 10
- 230000000144 pharmacologic effect Effects 0.000 claims abstract description 10
- 230000002459 sustained effect Effects 0.000 claims abstract description 9
- 150000001768 cations Chemical class 0.000 claims abstract description 8
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 8
- 239000000730 antalgic agent Substances 0.000 claims abstract description 6
- 230000003957 neurotransmitter release Effects 0.000 claims abstract description 6
- 229940035676 analgesics Drugs 0.000 claims abstract description 5
- 102000034573 Channels Human genes 0.000 claims abstract description 4
- 230000008587 neuronal excitability Effects 0.000 claims abstract description 4
- 239000002260 anti-inflammatory agent Substances 0.000 claims abstract description 3
- 229940121363 anti-inflammatory agent Drugs 0.000 claims abstract description 3
- 230000003227 neuromodulating effect Effects 0.000 claims abstract description 3
- 238000002560 therapeutic procedure Methods 0.000 claims abstract description 3
- 210000004027 cell Anatomy 0.000 claims description 77
- 230000014509 gene expression Effects 0.000 claims description 35
- 108091006146 Channels Proteins 0.000 claims description 21
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 20
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 17
- 229920001184 polypeptide Polymers 0.000 claims description 16
- 238000002360 preparation method Methods 0.000 claims description 16
- 239000000523 sample Substances 0.000 claims description 15
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 12
- 230000000295 complement effect Effects 0.000 claims description 12
- 238000009396 hybridization Methods 0.000 claims description 12
- 230000000692 anti-sense effect Effects 0.000 claims description 11
- 230000027455 binding Effects 0.000 claims description 10
- 239000012528 membrane Substances 0.000 claims description 10
- 230000004044 response Effects 0.000 claims description 10
- 230000001105 regulatory effect Effects 0.000 claims description 9
- 210000003594 spinal ganglia Anatomy 0.000 claims description 8
- 238000010367 cloning Methods 0.000 claims description 7
- 238000001415 gene therapy Methods 0.000 claims description 7
- 108091033319 polynucleotide Proteins 0.000 claims description 7
- 108090000994 Catalytic RNA Proteins 0.000 claims description 6
- 102000053642 Catalytic RNA Human genes 0.000 claims description 6
- 230000001965 increasing effect Effects 0.000 claims description 6
- 108091092562 ribozyme Proteins 0.000 claims description 6
- 238000013518 transcription Methods 0.000 claims description 6
- 230000035897 transcription Effects 0.000 claims description 6
- 239000000427 antigen Substances 0.000 claims description 5
- 108091007433 antigens Proteins 0.000 claims description 5
- 102000036639 antigens Human genes 0.000 claims description 5
- 210000000287 oocyte Anatomy 0.000 claims description 5
- 230000036407 pain Effects 0.000 claims description 5
- 210000000278 spinal cord Anatomy 0.000 claims description 5
- 102100022097 Acid-sensing ion channel 3 Human genes 0.000 claims description 4
- 101710099898 Acid-sensing ion channel 3 Proteins 0.000 claims description 4
- 230000003993 interaction Effects 0.000 claims description 4
- 230000009261 transgenic effect Effects 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 2
- 102000040430 polynucleotide Human genes 0.000 claims 6
- 239000002157 polynucleotide Substances 0.000 claims 6
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 230000002222 downregulating effect Effects 0.000 abstract description 3
- 239000002773 nucleotide Substances 0.000 description 29
- 125000003729 nucleotide group Chemical group 0.000 description 29
- 238000003752 polymerase chain reaction Methods 0.000 description 24
- 239000002299 complementary DNA Substances 0.000 description 21
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 19
- 108020004999 messenger RNA Proteins 0.000 description 10
- 238000006467 substitution reaction Methods 0.000 description 9
- 210000001519 tissue Anatomy 0.000 description 9
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 8
- 150000001413 amino acids Chemical class 0.000 description 8
- 230000003828 downregulation Effects 0.000 description 8
- 230000001939 inductive effect Effects 0.000 description 8
- 241000700159 Rattus Species 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 239000000556 agonist Substances 0.000 description 7
- 108091028043 Nucleic acid sequence Proteins 0.000 description 6
- 239000005557 antagonist Substances 0.000 description 6
- 210000003169 central nervous system Anatomy 0.000 description 6
- 239000013612 plasmid Substances 0.000 description 6
- 108010068806 Acid Sensing Ion Channels Proteins 0.000 description 5
- 102000001671 Acid Sensing Ion Channels Human genes 0.000 description 5
- 108091034117 Oligonucleotide Proteins 0.000 description 5
- 241000700584 Simplexvirus Species 0.000 description 5
- 230000004913 activation Effects 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 239000004031 partial agonist Substances 0.000 description 5
- 230000002441 reversible effect Effects 0.000 description 5
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 108091026890 Coding region Proteins 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 4
- 230000033228 biological regulation Effects 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 4
- 239000000975 dye Substances 0.000 description 4
- 238000004520 electroporation Methods 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 210000002569 neuron Anatomy 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 210000001044 sensory neuron Anatomy 0.000 description 4
- 239000013605 shuttle vector Substances 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 108020004705 Codon Proteins 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 102100034343 Integrase Human genes 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 238000000636 Northern blotting Methods 0.000 description 3
- 108700026244 Open Reading Frames Proteins 0.000 description 3
- 206010046865 Vaccinia virus infection Diseases 0.000 description 3
- 241000269370 Xenopus <genus> Species 0.000 description 3
- 238000007792 addition Methods 0.000 description 3
- 239000011543 agarose gel Substances 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 239000007975 buffered saline Substances 0.000 description 3
- 229910001424 calcium ion Inorganic materials 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000000977 initiatory effect Effects 0.000 description 3
- 150000002500 ions Chemical class 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 230000010076 replication Effects 0.000 description 3
- 108091008146 restriction endonucleases Proteins 0.000 description 3
- 229910001415 sodium ion Inorganic materials 0.000 description 3
- 238000000638 solvent extraction Methods 0.000 description 3
- 208000007089 vaccinia Diseases 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 2
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 2
- FKNQFGJONOIPTF-UHFFFAOYSA-N Sodium cation Chemical compound [Na+] FKNQFGJONOIPTF-UHFFFAOYSA-N 0.000 description 2
- 108091036066 Three prime untranslated region Proteins 0.000 description 2
- 241000700618 Vaccinia virus Species 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 230000003196 chaotropic effect Effects 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 239000003184 complementary RNA Substances 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 229960000633 dextran sulfate Drugs 0.000 description 2
- 229910000397 disodium phosphate Inorganic materials 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000000763 evoking effect Effects 0.000 description 2
- 230000003492 excitotoxic effect Effects 0.000 description 2
- 231100000063 excitotoxicity Toxicity 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 230000004907 flux Effects 0.000 description 2
- -1 from spinal cord Chemical class 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 231100000219 mutagenic Toxicity 0.000 description 2
- 230000003505 mutagenic effect Effects 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 230000004481 post-translational protein modification Effects 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 238000010839 reverse transcription Methods 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 238000002741 site-directed mutagenesis Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 230000000946 synaptic effect Effects 0.000 description 2
- 230000001052 transient effect Effects 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 102100022094 Acid-sensing ion channel 2 Human genes 0.000 description 1
- 208000010444 Acidosis Diseases 0.000 description 1
- 241000186361 Actinobacteria <class> Species 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- 108020004491 Antisense DNA Proteins 0.000 description 1
- 108020005544 Antisense RNA Proteins 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 102000007527 Autoreceptors Human genes 0.000 description 1
- 108010071131 Autoreceptors Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 108700010070 Codon Usage Proteins 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 239000003298 DNA probe Substances 0.000 description 1
- 108010033806 Degenerin Sodium Channels Proteins 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 102000004533 Endonucleases Human genes 0.000 description 1
- 108091060211 Expressed sequence tag Proteins 0.000 description 1
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
- 108700007698 Genetic Terminator Regions Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 101000754290 Homo sapiens Acid-sensing ion channel 1 Proteins 0.000 description 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- 101710203526 Integrase Proteins 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 108091093037 Peptide nucleic acid Proteins 0.000 description 1
- NPYPAHLBTDXSSS-UHFFFAOYSA-N Potassium ion Chemical compound [K+] NPYPAHLBTDXSSS-UHFFFAOYSA-N 0.000 description 1
- 244000028344 Primula vulgaris Species 0.000 description 1
- 235000016311 Primula vulgaris Nutrition 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 108091081021 Sense strand Proteins 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 241000251131 Sphyrna Species 0.000 description 1
- 241000529895 Stercorarius Species 0.000 description 1
- 208000037065 Subacute sclerosing leukoencephalitis Diseases 0.000 description 1
- 206010042297 Subacute sclerosing panencephalitis Diseases 0.000 description 1
- 101710192266 Tegument protein VP22 Proteins 0.000 description 1
- 108700005077 Viral Genes Proteins 0.000 description 1
- 230000007950 acidosis Effects 0.000 description 1
- 208000026545 acidosis disease Diseases 0.000 description 1
- XSDQTOBWRPYKKA-UHFFFAOYSA-N amiloride Chemical compound NC(=N)NC(=O)C1=NC(Cl)=C(N)N=C1N XSDQTOBWRPYKKA-UHFFFAOYSA-N 0.000 description 1
- 229960002576 amiloride Drugs 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 239000003816 antisense DNA Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 108091036078 conserved sequence Proteins 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 1
- SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000002001 electrophysiology Methods 0.000 description 1
- 230000007831 electrophysiology Effects 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 230000006539 extracellular acidification Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- YFHXZQPUBCBNIP-UHFFFAOYSA-N fura-2 Chemical compound CC1=CC=C(N(CC(O)=O)CC(O)=O)C(OCCOC=2C(=CC=3OC(=CC=3C=2)C=2OC(=CN=2)C(O)=O)N(CC(O)=O)CC(O)=O)=C1 YFHXZQPUBCBNIP-UHFFFAOYSA-N 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 210000001320 hippocampus Anatomy 0.000 description 1
- 102000048484 human ASIC1 Human genes 0.000 description 1
- 210000003016 hypothalamus Anatomy 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 230000013016 learning Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000028161 membrane depolarization Effects 0.000 description 1
- 230000015654 memory Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 230000000324 neuroprotective effect Effects 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000006174 pH buffer Substances 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 238000012402 patch clamp technique Methods 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 102000054765 polymorphisms of proteins Human genes 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 229910001414 potassium ion Inorganic materials 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000002708 random mutagenesis Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 210000002504 synaptic vesicle Anatomy 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 description 1
- 150000003568 thioethers Chemical class 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Definitions
- the present invention relates to proton or acid-sensing ion channels and nucleic acid encoding the same. It further relates to methods and materials for generating and using these.
- Acidosis accompanies many painful inflammatory and ischaemic conditions.
- the pain caused by acids is thought to be mediated in part by H+-gated cation channels present in sensory neurons.
- H+-gated cation channels are of interest, inter alia , in the treatment of inflammation or other painful conditions e.g. through the use of targeted analgesics.
- ASIC acid-sensing ionic channel
- rat aldmann et al . (1997) Nature 386, 6621, pl73-177. This belongs to the amiloride-sensitive Na+ channel/degenerin family of ion channels (see Waldmann and Lazdunski 1998, Current Biology 8: 418-424).
- ASIC amiloride- sensitive cation
- Ca2+> K+ amiloride-sensitive cation
- the biophysical and pharmacological properties of the ASIC channel closely match one of the H+-gated cation channels described in sensory neurons.
- ASIC is also distributed widely throughout the brain. Owing to the interest in H+-gated cation channels, it will be appreciated that the provision of a new channel, particularly one having one or more novel activities compared to those already available to the public, would provide a contribution to the art .
- the present inventors have now cloned nucleic acid encoding a novel H+-gated cation channel from a rat sensory neuron cDNA library, and isolated and characterised the encoded protein.
- the nucleic acid sequence is shown as Seq ID No 1, while the encoded protein is Seq ID No 2.
- the channel which is present in both spinal cord and throughout the central nervous system in subsets of neurons, is hereinafter referred to as "SPASIC" .
- the inventors used molecular cloning techniques to characterise the SPASIC protein.
- si tu DNA hybridisation and RNA Northern blotting showed that the new channel transcripts are present in dorsal root ganglion neurons and in central nervous system tissues.
- the channel When expressed in transfected COS cells, the channel mediated both a transient and a sustained flow of current when exposed to extracellular acidity, e.g. of below pH
- SPASIC shares 43% sequence identity with ASIC (the amino acid sequence of which is shown as Seq ID No 3) and has similarities with other characterised ASIC-type proteins (see Figure 2) .
- SPASIC has unique properties. In particular it exhibits both a rapid, and then a sustained cation current in response to low pH. No H+-gated channel having these properties has been characterised before .
- this new channel is an analgesic drug target and has utility, inter alia, in screening techniques for identifying novel analgesic and anti- inflammatory agents.
- the channel also has utility in screening for agents that regulate neurotransmitter release or neuronal excitability, including the regulation of excitotoxicity and synaptic efficacy (e.g. in the context of learning and memory, cognition, perception, pain etc, depending inter alia on the location in which the channel may be expressed) .
- an acid sensitive cation channel protein which is capable of reversibly mediating (i) a rapid, and (ii) a sustained cation current.
- Proteins, or polypeptides , of the present invention may be provided in recombinantly produced, isolated, enriched or cell-free form. They may be present in cells heterologously, which is to say that they do not naturally occur there, but have been introduced through human intervention.
- acid sensitive is meant that the cation permeability of the channel can be significantly increased by lowering the pH (increasing acidity, or reducing alkalinity) .
- the mediated current will occur in two phases, a "rapid" phase, and a "sustained” phase.
- the rapid phase will last less than 500 milliseconds, more commonly less than about 200 milliseconds.
- the sustained phase will generally continue for the period in which the pH stimulus is maintained.
- the two phase activity can be assessed by those skilled in the art without undue burden, for instance using voltage clamping techniques analogous to those described herein to analyse membranes or membrane preparations (e.g. from eucaryotic cells) into which the protein has been expressed or otherwise introduced. Some generally applicable methods are discussed in "Ionic Channels of Excitable Membranes” Hille, B. - Pub 1992, Sinauer.
- the protein will have the electrophysiological and pharmacological characteristics of the SPASIC protein described herein.
- the protein comprises amino acid sequence Seq ID No 2.
- a SPASIC variant protein having ion channel activity and comprising an amino acid sequence having at least about 50%, or 60%, or 70%, or 80% homology, most preferably at least about 90%, 95%, 96%, 97%, 98% or 99% sequence identity with Seq ID No 2.
- Ion channel activity may be tested as described above, using appropriate stimuli if required.
- Similarity may be as defined and determined by the TBLASTN program, of Altschul et al . (1990) J " . Mol . Biol . 215: 403-10, which is in standard use in the art, or, and this may be preferred, the standard program BestFit, which is part of the Wisconsin Package, Version 8, September 1994, (Genetics Computer Group, 575 Science Drive, Madison, Wisconsin, USA, Wisconsin 53711) . BestFit makes an optimal alignment of the best segment of similarity between two sequences. Optimal alignments are found by inserting gaps to maximize the number of matches using the local homology algorithm of Smith and Waterman.
- Homology may be over the full-length of the relevant sequence shown herein, or may be over a part of it, preferably over a contiguous sequence of about or greater than about 20, 25, 30, 33, 40, 50, 67, 133, 167, 200, 233 or more amino acids or compared with Seq ID No 2.
- a variant polypeptide in accordance with the present invention may include within the sequence shown in Seq ID No 2 , a single amino acid or 2, 3, 4, 5, 6, 7, 8, or 9 changes, about 10, 15, 20, 30, 40 or 50 changes, or greater than about 50, 60, 70, 80 or 90 changes.
- a variant polypeptide may include additional amino acids at the C-terminus and/or N- terminus. Alternatively it may represent an active (as an ion channel) fragment of the protein e.g. a pore forming fragment .
- Proteins or polypeptides of the present invention may be prepared by the expression of nucleic acids encoding therefor in appropriate host cells, as described in more detail hereinafter..
- nucleic encoding a protein of the invention as described above .
- Nucleic acid according to the present invention may include cDNA, RNA, genomic DNA and modified nucleic acids or nucleic acid analogs (e.g. peptide nucleic acid). Where a DNA sequence is specified, e.g. with reference to a figure, unless context requires otherwise the RNA equivalent, with U substituted for T where it occurs, is encompassed.
- Nucleic acid molecules according to the present invention may be provided isolated and/or purified from their natural environment, in substantially pure or homogeneous form, or free or substantially free of other nucleic acids of the species of origin. Where used herein, the term “isolated” encompasses all of these possibilities.
- the nucleic acid molecules may be wholly or partially synthetic. In particular they may be recombinant in that nucleic acid sequences which are not found together in nature (do not run contiguously) have been ligated or otherwise combined artificially. Alternatively they may have been synthesised directly e.g. using an automated synthesiser.
- nucleic acid encoding SPASIC e.g. a nucleic acid encoding Seq ID No 2 (which nucleic acid sequence is set out as bases 292-1909 in Seq ID No 1) .
- sequence degeneratively equivalent to that sequence there is disclosed.
- nucleic acid which encodes a SPASIC variant as described above.
- this will share homology or identity with the SPASIC encoding sequence in similar terms as are described in relation to the variant proteins above, but wherein amino changes correspond to changes in codons or individual nucleotides.
- Variants may include distinctive parts or fragment (however produced) corresponding to a portion of the sequence provided.
- the fragments may encode particular functional parts of the polypeptide.
- fragments may have utility in probing for, or amplifying, the sequence provided or closely related ones. Suitable lengths of fragment, and conditions, for such processes are discussed in more detail below.
- nucleic acids which have been extended at the 3 ' or 5 ' terminus with respect any of these embodiments.
- Preferred variant nucleic acids are those which, in addition to encoding SPASIC variants, are capable of hybridizing with at least one poly- or oligonucleotide of sequence selected from sequence of SEQ ID No 1 under low stringency conditions, more preferably being capable of hybridizing with one or more of such sequences under high stringency conditions.
- SSC Standard Saline Citrate
- the screening is carried out at about 37°C, a formamide concentration of about 20%, and a salt concentration of about 5 X SSC, or a temperature of about 50°C and a salt concentration of about 2 X SSPE.
- Suitable conditions include, e.g. for detection of sequences that are about 80-90% identical, hybridization overnight at 42°C in 0.25M Na 2 HP0 4 , pH 7.2 , 6.5% SDS, 10% dextran sulfate and a final wash at 55°C in 0. IX SSC, 0.1% SDS.
- suitable conditions include hybridization overnight at 65°C in 0.25M Na 2 HP0 4 , pH 7.2, 6.5% SDS, 10% dextran sulfate and a final wash at 60°C in 0.1X SSC, 0.1% SDS.
- Sequence variants which occur naturally may include alleles (which will include polymorphisms or mutations at one or more bases) or pseudoalleles . Also included within the scope of the present invention would be isogenes, or other homologous genes sharing the requisite identity with SPASIC.
- the term 'variant' nucleic acid as used herein encompasses all of these possibilities.
- a method of identifying and/or cloning a nucleic acid according to the present invention which method employs Seq ID No 1 or a distinctive fragment thereof.
- nucleotide sequence information provided herein may be used m a data-base (e.g. of expressed sequence tags, or sequence tagged sites) search to find homologous sequences, such as those which may become available in due course, and expression products of which can be tested for activity as described below.
- a data-base e.g. of expressed sequence tags, or sequence tagged sites
- a variant in accordance with the present invention is also obtainable by means of a method which includes:
- nucleic acid e.g. from spinal cord
- nucleic acid in said preparation with said nucleic acid molecule under conditions for hybridisation of said nucleic acid molecule to any said gene or homologue in said preparation, and identifying said gene or homologue if present by its hybridisation with said nucleic acid molecule.
- Probing may optionally be done by means of so-called 'nucleic acid chips' (see Marshall & Hodgson (1998) Nature Biotechnology 16: 27-31, for a review) .
- Nucleic acids of the invention may be amplified from template DNA from cells using a specific DNA amplification reaction with specific primers targeted to amplify the DNA required, e.g. of SEQ ID No 1, e.g. from genomic DNA, spinal cord or DRG cDNA, or mRNA templates, e.g. by using polymerase chain reaction or, from RNA, by using reverse transcription (RT) followed by polymerase chain reaction (PCR) (see "PCR protocols; A Guide to
- a method involving use of PCR in obtaining nucleic acid according to the present invention may include:
- nucleic acid e.g. from the CNS , or other appropriate tissue or organ
- tissue derived libraries of genomic DNA or cDNA or mRNA for DNA or RNA of the invention it will be convenient to use low then high stringency hybridization techniques as indicated above. Such screening may be carried out using hybridization probes targeted at all or part of SEQ ID No 1.
- specific amplification primers ie. PCR primers
- PCR primers may be used to amplify homologous sequences native to the source DNA to be used as PCR template and the product DNA may be used as a specific probe when labelled to identify DNA of the invention from the genomic, cDNA or mRNA library material .
- clones or fragments identified in the search can be extended. For instance if it is suspected that they are incomplete, the original DNA source (e.g. a clone library, mRNA preparation etc.) can be revisited to isolate missing portions e.g. using sequences, probes or primers based on that portion which has already been obtained to identify other clones containing overlapping sequence .
- the original DNA source e.g. a clone library, mRNA preparation etc.
- Distinctive fragments or oligonucleotides for use in probing or PCR may be selected prepared by those skilled in the art without burden in the light of the present disclosure. Typically they may be about 10 to 30 or fewer nucleotides in length (e.g. 18, 21 or 24) . Generally specific primers are upwards of 14 nucleotides in length. For optimum specificity and cost effectiveness, primers of 16-24 nucleotides in length may be preferred. If required, probing can be done with entire restriction fragments of the gene diclosed herein which may be 100 's or even 1000 's of nucleotides in length.
- probes and primers capable of hybridizing with those regions of the SEQ ID No 1 which are highly conserved between SPASIC and other ion channels (DRASIC, ⁇ -ASIC, ⁇ ASIC) . These regions can be identified from the amino acid sequence alignments disclosed herein. Highly conserved, as will be understood by those skilled in the art, means that degenerate primers can be devised which will amplify nucleic acids having the sequence characteristics of both SPASIC and the other ion channel .
- probes or primers corresponding to all or a major part of the sequence of SEQ ID No 1, or to those parts of the sequence that are not well conserved between the different types of ASIC channel protein.
- Example regions include those amplified by the primers set out herein.
- Seq ID Nos 4 to 9 Preferred Examples are shown in Seq ID Nos 4 to 9. These are adapted to amplify the entire ORF (Seq ID No 4 and 5) , a unique SPASIC portion for probing (Seq ID No 6 and 7) and degenerate primers having utility in finding new members of the ASIC family (Seq ID No 8 to 9) .
- probes and primers of the invention will occur to those skilled in the art by alignment of the present sequence SEQ ID No 1 with the other known ASIC protein sequences. It will be realised that, where the nucleic acids of the present invention are provided in double stranded form, such probes and primers may be targeted at either strand. Such probes, primers and oligonucleotides are provided by a further aspect of the invention and may be used m amplification reactions, or Southern or Northern blotting procedures .
- variants may be prepared by those skilled m the art on the basis of the sequences provided herein, for instance by site directed or random mutagenesis, or by direct synthesis.
- the variant nucleic acid is generated either directly or indirectly (e.g. via one or amplification or replication steps) from an original nucleic acid having all or part of the sequence shown m Seq ID No 1.
- a further aspect of the invention there is disclosed a method of producing a derivative nucleic acid comprising the step of modifying the coding sequence of Seq ID No 1.
- Changes to a sequence, to produce a derivative may be by one or more of addition, insertion, deletion or substitution of one or more nucleotides m the nucleic acid, leading to the addition, insertion, deletion or substitution of one or more ammo acids m the encoded polypeptide.
- Changes may be desirable for a number of reasons, including introducing or removing the following features: restriction endonuclease sequences; codon usage; other sites which are required for post translation modification; cleavage sites m the encoded polypeptide; motifs m the encoded polypeptide for post-translational modification.
- Leader or other targeting sequences e.g. membrane or golgi locating sequences
- All of these may assist in efficiently cloning and expressing an active polypeptide in recombinant form (as described below) .
- Other desirable mutation may be random (e.g. chemical) or site directed mutagenesis in order to alter the activity (e.g. specificity) or stability of the encoded polypeptide.
- a vectorised DNA of SEQ ID No 1 is exposed to a mutagenic material such as hydroxylamine, or, in the case of SDM, a PCR reaction is carried out on that DNA using a mutagenic primer, whereby DNA is produced which encodes for a protein different in sequence to SEQ ID No 2 at a few predictable or predetermined sites respectively.
- Particular target areas of the sequence are those which may determine any of the following: specificity of activation of the ion channel (e.g. required pH change); nature of response (e.g. transient, sustained current); specificity of ion channel (e.g. relative permeability to different cations) .
- specificity of activation of the ion channel e.g. required pH change
- nature of response e.g. transient, sustained current
- specificity of ion channel e.g. relative permeability to different cations
- amino acid sequence differs from SEQ ID No 2 only by conservative substitutions.
- the expression 'conservative substitutions' as used with respect to amino acids relates to the substitution of a given amino acid by an amino acid having physicochemical characteristics in the same class.
- an amino acid in SEQ ID No 2 has a hydrophobic characterising group
- a conservative substitution replaces it by another amino acid also having a hydrophobic characterising group; other such classes are those where the characterising group is hydrophilic, cationic, anionic or contains a thiol or thioether.
- substitutions are well known to those of ordinary skill in the art, i.e. see US 5380712, and are only contemplated where the resultant protein has ion channel activity.
- variants having non-conservative substitutions are also included. As is well known to those skilled in the art, substitutions to regions of a peptide which are not critical in determining its conformation may not greatly affect its activity because they do not greatly alter the peptide 's three dimensional structure. In regions which are critical in determining the peptides conformation or activity such changes may confer advantageous properties on the polypeptide.
- a quite different approach may include mixing or incorporating sequences from related ASIC-type genes into the SPASIC sequence.
- restriction enzyme fragments of SPASIC could be ligated together with fragments of a SPASIC homologue or even of an unrelated gene to generate recombinant variants of SPASIC (so called ⁇ DNA shuffling' - see Crameri et al . , 1998, Nature 391 . ) .
- the nucleic acids of the present invention are in the form of a recombinant and preferably replicable constructs, such as vectors.
- Vector is defined to include, inter alia, any plasmid, cosmid, phage or other vector in double or single stranded linear or circular form which may or may not be self transmissible or mobilizable, and which can transform prokaryotic or eukaryotic host either by integration into the cellular genome or exist extrachromosomally (e.g. autonomous replicating plasmid with an origin of replication) .
- shuttle vectors by which is meant a DNA vehicle capable, naturally or by design, of replication in two different host organisms, which may be selected from actinomycetes and related species, bacteria and eucaryotic (e.g. mammalian, yeast or fungal cells) .
- a vector including nucleic acid according to the present invention need not include a promoter or other regulatory sequence, particularly if the vector is to be used to introduce the nucleic acid into cells for recombination into the genome .
- the nucleic acid in the vector is under the control of, and operably linked to, an appropriate promoter or other regulatory elements for transcription in a host cell such as a microbial, e.g. bacterial cell.
- a host cell such as a microbial, e.g. bacterial cell.
- the vector may be a bi-functional expression vector which functions in multiple hosts. In the case of genomic SPASIC DNA (isolatable as described above) this may contain its own promoter or other regulatory elements and in the case of cDNA this may be under the control of an appropriate promoter or other regulatory elements for expression in the host cell.
- promoter is meant a sequence of nucleotides from which transcription may be initiated of DNA operably linked downstream (i.e. in the 3' direction on the sense strand of double-stranded DNA) .
- operably linked means joined as part of the same nucleic acid molecule, suitably positioned and oriented for transcription to be initiated from the promoter.
- DNA operably linked to a promoter is "under transcriptional initiation regulation" of the promoter.
- this aspect of the invention provides a gene construct, preferably a replicable vector, comprising a promoter operatively linked to a nucleotide sequence provided by the present invention, such as the SPASIC gene (see Seq ID NO 1) or a variant thereof.
- a promoter operatively linked to a nucleotide sequence provided by the present invention, such as the SPASIC gene (see Seq ID NO 1) or a variant thereof.
- Suitable vectors can be chosen or constructed, containing appropriate regulatory sequences, including promoter sequences, terminator fragments, polyadenylation sequences, enhancer sequences, marker genes and other sequences as appropriate.
- appropriate regulatory sequences including promoter sequences, terminator fragments, polyadenylation sequences, enhancer sequences, marker genes and other sequences as appropriate.
- this aspect of the present invention provides a gene construct, preferably a replicable vector, comprising an inducible promoter operatively linked to a nucleotide sequence provided by the present invention, such as Seq ID No 1.
- an inducible promoter operatively linked to a nucleotide sequence provided by the present invention, such as Seq ID No 1.
- the term "inducible” as applied to a promoter is well understood by those skilled in the art. In essence, expression under the control of an inducible promoter is "switched on” or increased in response to an applied stimulus. The nature of the stimulus varies between promoters. Some inducible promoters cause little or undetectable levels of expression (or no expression) in the absence of the appropriate stimulus. Other inducible promoters cause detectable constitutive expression in the absence of the stimulus. Whatever the level of expression is in the absence of the stimulus, expression from any inducible promoter is increased in the presence of the correct stimulus.
- vectors suitable for expression of mammalian DNA such as will occur to those skilled in the art, e.g. HSV or vaccinia vectors, or pcDNA3 shuttle vectors, e.g. as included within the lambda express system (Stratagene) , which are capable of expressing heterologous protein in both bacteria and in eucaryotic cells such as COS cells.
- Suitable bacterial vectors will include lambda-Zap vectors such as the lambda-Zap-II vector available from Stratagene Cloning Systems .
- Bacterial clones containing plasmids capable of gene expression can be obtained by excising pBluescript from the lambda-Zap-II construct in the presence of a filamentous helper phage also available from Stratagene. Typical protocols are provided in the examples below, or in commercially available Stratagene kits.
- a further aspect of the present invention provides cells containing, or more preferably transformed with (or transfected with) the nucleic acids of the present invention.
- Such cells are provided by transformation of a host cell, preferably a eucaryotic cell, e.g. a COS, CHO or HEK 293 cell or an oocyte, preferably a Xenopus oocyte, particularly COS cells, using DNA of the invention as incorporated by recombinant DNA techniques into a vector or as directly incorporated into the cells ' genomic DNA e.g. by electroporation or other such DNA integrating technique.
- a host cell preferably a eucaryotic cell, e.g. a COS, CHO or HEK 293 cell or an oocyte, preferably a Xenopus oocyte, particularly COS cells
- Such cells may be capable of expressing, or having expressed, a SPASIC protein as described hereinabove.
- the cells may thus mimic, in some respects, the electrophysiological and pharmacological properties of native SPASIC-expressing cells
- RNA of the present invention it is possible to produce cells bearing the receptor protein of the invention by direct injection of RNA of the present invention, into the cells wherein it becomes translated.
- RNA of the present invention it is possible to achieve the presence of functioning SPASIC protein on cell membranes within 3 days such that it is ready for electrophysiological and pharmacological study.
- down-regulation of expression of a target gene may be achieved using anti-sense technology.
- RNA is placed under the control of a promoter in a "reverse orientation" such that transcription yields RNA which is complementary to normal mRNA transcribed from the "sense" strand of the target gene.
- Antisense technology is also reviewed in Bourque, (1995) , Plant Science 105, 125-149, and Flavell, (1994) PNAS USA 91, 3490-3496.
- “Complementary to” means that the capable of base pairing with whereby A is the complement of T (and U) ; G is the complement of C.
- An alternative to anti-sense is to use a copy of all or part of the target gene inserted in sense, that is the same, orientation as the target gene, to achieve reduction in expression of the target gene by co- suppression.
- ribozymes e.g. hammerhead ribozymes, which can catalyse the site-specific cleavage of RNA, such as mRNA (see e.g. Jaeger (1997) “The new world of ribozymes” Curr Opin Struct Biol 7:324-335, or Gibson & Shillitoe (1997) “Ribozymes : their functions and strategies form their use” Mol Biotechnol 7: 242-251.)
- RNA such as mRNA
- Anti-sense or sense or ribozyme based regulation may be performed using vectors as described above, and may itself be regulated by employing an inducible promoter in an appropriate construct .
- incorporation of this DNA into mammalian cells might be readily accomplished using vectors, e.g. such as HSV, vaccinia or adenovirus (see Principles of Gene Manipulation (1994) 5th Edit. Old and Primrose 5th Edition, Blackwell Scientific Publications) .
- the complete sequence corresponding to the coding sequence need not be used. For example fragments of sufficient length may be used. It is a routine matter for the person skilled in the art to screen fragments of various sizes and from various parts of the coding sequence to optimise the level of anti-sense inhibition. It may be advantageous to include the initiating methionine ATG codon, and perhaps one or more nucleotides upstream of the initiating codon. A further possibility is to target a conserved sequence of a gene, e.g. a sequence that is characteristic of one or more genes, such as a regulatory sequence.
- the sequence employed may be about 500 nucleotides or less, possibly about 400 nucleotides, about 300 nucleotides, about 200 nucleotides, or about 100 nucleotides. It may be possible to use oligonucleotides of much shorter lengths, 14-23 nucleotides, although longer fragments, and generally even longer than about 500 nucleotides are preferable where possible, such as longer than about 600 nucleotides, than about 700 nucleotides, than about 800 nucleotides, than about 1000 nucleotides or more.
- sequence employed in a down-regulation of gene expression in accordance with the present invention may be a wild-type sequence (e.g. gene) selected from those available, or a variant of such a sequence.
- the sequence need not include an open reading frame or specify an RNA that would be translatable. It may be preferred for there to be sufficient homology for the respective anti-sense and sense RNA molecules to hybridise. There may be down regulation of gene expression even where there is about 5%, 10%, 15% or 20% or more mismatch between the sequence used and the target gene. Effectively, the homology should be sufficient for the down-regulation of gene expression to take place.
- One embodiment of this aspect of the invention employs DNA oligonucleotides, typically being of 10 to-30-bases long, conveniently about 20 bases long, optionally in degradation protected form, e.g. by being thiolated, and which conveniently have been chemically synthesized to be directed to hybridize with a part of the 5' coding region of the SPASIC mRNA.
- Annealing with the oligomeric DNA causes the mRNA to be degraded by activation of RNase H, or blocks the translation of the mRNA into protein.
- the small size of such oligomers facilitates their direct access into target cells which express the present ASIC proteins.
- An alternative embodiment produces antisense RNA in vivo by inserting a tissue specific inducible or constitutively active promoter, enhancer or locus control region or element upstream of the coding region, or part of the coding region, of DNA of SEQ ID No 1 in a construct which is then cloned into a vector.
- a tissue specific inducible or constitutively active promoter, enhancer or locus control region or element upstream of the coding region, or part of the coding region of DNA of SEQ ID No 1 in a construct which is then cloned into a vector.
- a vector For use in mammals in therapy such a vector should be capable of infecting but not killing target cells.
- Convenient vectors for use in this embodiment which can target mammalian dorsal root ganglion cells are Herpes Simplex Virus (HSV) vaccinia or adenovirus derived vectors. Viral vectors for use in gene therapy are discussed by Vile (1997) Nature Biotechnology 15: 840-8
- the antisense down-regulating DNA or RNA is provided in dorsal root ganglia cells it potentially inhibits the pain response by actually decreasing the number of SPASIC channels on the surface of sensory cells.
- the antisense down-regulating DNA or RNA is provided in the central nervous system, it alters neurotransmitter release by actually decreasing the number of SPASIC channels on the surface of neurons.
- nucleotide sequence which is complementary to any of the coding-nucleic acids discussed in relation to earlier aspects of the invention forms one part of the present invention.
- the invention further provides a method of influencing the electrophysiological and pharmacological properties of a cell, said method comprising the step of causing or allowing expression of a heterologous nucleic acid sequence as discussed above within that cells, which may optionally be within an organism.
- the present invention further provides the use of the nucleotide sequence of Seq ID No 1, or its complement, or a variant of either for down-regulation of gene expression, particularly down-regulation of expression of an ion channel-encoding gene, more preferably a cation channel, most preferably SPASIC.
- nucleic acid e.g. antisense DNA
- nucleic acid of the present invention for use m gene therapy, or for use m the preparation of medicaments for use m gene therapy.
- an organism preferably a non-human mammal, comprising cells m which the activity of SPASIC or a variant thereof have been altered, preferably impaired, by use of the methods and materials discussed above.
- a rodent e.g. munne organism.
- Methods of producing 'knock out' mammals m which specific gene activities have been impaired are now well known to those skilled m the art - see e.g. Boer ⁇ gter et al (1995) Nature 377: 657-659, or Gossen and Vi k (1993) Trends Genet 9: 27-31.
- Such substances may, for instance, act as agonist, partial agonist or antagonist.
- the protein or cell may be used m a method comprising exposing the protein (e.g which is associated with a membrane, for instance of a liposome) or cell surface to a solution of the substance such as to allow interaction between the substance and the SPASIC (or variant SPASIC) protein m the membrane and then measuring the electrophysiological response of the cell or membrane to this interaction. This measurement may optionally be compared with a reference figure.
- the protein e.g which is associated with a membrane, for instance of a liposome
- SPASIC or variant SPASIC
- the response may be measured by use of a microelectrode technique accompanied by such measurement strategies as voltage clamping of the cell whereby activation of ion channels may be identified by inward or outward current flow as detected using the microelectrodes .
- 22 Na, 86 Rb, 45 Ca radiolabeled cations or 14 C or 3 H guanidine may be used to assess such ion flux;
- a sodium, calcium or potassium ion sensitive dye such as Fura-2, or indo
- a potential sensitive dye may be used to monitor potential changes, e.g. such as m depolarization
- Agonists and partial agonists may be identified by their relative efficacy as compared to extracellular acid pH or other known agonists m activating the receptor or, m the case of partial agonists and antagonists, by their ability to block the activation caused by a given acidity, for example pH 6 , or other known agonists.
- Such substances will have potential as analgesics or other neuromodulatory agents, and as such form a further aspect of the present invention, optionally m the form medicamanents (e.g. compositions comprising a pharmaceutically acceptable carrier or filler) .
- medicamanents e.g. compositions comprising a pharmaceutically acceptable carrier or filler
- Purified SPASIC protein or a variant thereof, e.g. produced recombinantly by expression from encoding nucleic acid therefor, may be used to raise antibodies employing techniques which are standard in the art .
- Antibodies and polypeptides comprising antigen-binding fragments of antibodies may be used (inter alia) as antagonists or inhibitors, or for use in identifying homologues .
- Methods of producing antibodies include immunising a mammal with the protein or a fragment thereof.
- Antibodies may be obtained from immunised animals using any of a variety of techniques known in the art, and might be screened, preferably using binding of antibody to antigen of interest.
- Antibodies may be polyclonal or monoclonal.
- Antibodies may be modified in a number of ways. Indeed the term “antibody” should be construed as covering any specific binding substance having a binding domain with the required specificity. Thus, this term covers antibody fragments, derivatives, functional equivalents and homologues of antibodies, including any polypeptide comprising an immunoglobulin binding domain, whether natural or synthetic. Chimaeric molecules comprising an immunoglobulin binding domain, or equivalent, fused to another polypeptide are therefore included. Cloning and expression of Chimaeric antibodies are described in EP-A- 0120694 and EP-A-0125023. It has been shown that fragments of a whole antibody can perform the function of binding antigens.
- binding fragments are (i) the Fab fragment consisting of VL, VH, CL and CHI domains; (ii) the Fd fragment consisting of the VH and CHI domains; (iii) the Fv fragment consisting of the VI and VH domains of a single antibody; (iv) the dAb fragment (Ward, E.S. et al . , Nature 341, 544-546 (1989) which consists of a VH domain; (v) isolated CDR regions;
- F(ab')2 fragments a bivalent fragment comprising two linked Fab fragments
- Fab fragments a bivalent fragment comprising two linked Fab fragments
- Fig 1 Aligned amino acid sequences of SPASIC (protein of present invention) , DRASIC (see Waldmann and Lazdunski 1998, Current Biology 8: 418-424); ASIC-alpha (also referred to as 'ASIC - see also Waldmann and Lazdunski supra) ; ASIC-beta (GB 9718365.1 - unpublished at the filing date of the present application) .
- Trans-membrane helices TM1/TM2
- Fig 2 Shows a time-course the inward current (in pA) evoked by application of low pH (about 5) to a COS cell expressing SPASIC. The characteristic sustained inward current is clearly visible.
- SEQ ID No 1 cDNA corresponding to SPASIC cDNA as derived from Rattus norveqicus dorsal root ganglia cells.
- SEQ ID No 2 Amino acid sequence of SPASIC protein from Rattus norveqicus dorsal root ganglia cells.
- SEQ ID No 3 Amino acid sequence of ASIC protein of the prior art .
- SEQ ID No 4 Primer for use with that of SEQ ID No 5 PCR screening (253-277)
- SEQ ID No 5 Primer for use with that of SEQ ID No 4 in PCR screening (reverse 1955-1980)
- SEQ ID No 6 Primer for use with that of SEQ ID No 7 in PCR screening (419-438)
- SEQ ID No 7 Primer for use with that of SEQ ID No 6 in PCR screening (reverse 984-1008)
- SEQ ID No 8 Primer for use with that of SEQ ID No 9 in degenerate PCR screening (corresponds to ammo acid sequence RYG/AKEI/LSM - numbers 379-386) .
- SEQ ID No 9 Primer for use with that of SEQ ID No 8 PCR screening (corresponds, m reverse, to ammo acid sequence GLFIGASI/L m the TM2 region of Figure 2 - numbers 438-445) .
- the rat ASIC-beta clone (Patent application GB 9718365.1) was used to probe a cDNA library. 10 6 clones from a size fractionated (2-4kb) DRG cDNA library were amplified on HyBond N+ filters (Amersham) prior to hybridisation (Woo et al . PNAS (1978) 75, 3688) 32-P dATP random-primed ASIC-beta EcoRI probe (position 1-2087) was used to probe the library. The filters were hybridised at low stringency m 6 x SSC, 0.5% SDS, 5 x Denhardt ' s solution, with 200 micrograms/ml boiled salmon sperm DNA at 53°C. The filters were washed briefly m 4 x SSC at room temperature, then twice m 2 x SSC with 0.5% SDS at 55°C for 20 minutes. The filters were autoradiographed for 3 days on Kodak X-Omat films.
- the ASIC-beta EcoRI probe (position 1-2087) was also used for high stringency screening where the filters were given a final wash m 0.1 x SSC, 0.5% SDS at 68°C (Chen et al. 1995 Nature 377, 428-432) . Plaques that hybridised at low stringency but not at high stringency were selected for secondary screening, followed by cross- hyb ⁇ disation. Full length SPASIC clones were isolated Example 2: Preparation of cDNA from E. coli
- Bluescript plasmid DNA encoding for the protein of the invention was purified from the E. coli DNA by solvent extraction, Magic minipreps or Caesium chloride centrifugation, and digested with endonucleases EcoRI and Xhol targeted at the 3 ' -polylinker downstream of the cDNA and the site of the vector bacteriophage polymerase.
- Example 3 Homology Cloning of other mammalian SPASIC using sequence derived from the rat cDNA clone.
- RNA is extracted from the isolated tissue by extraction in guanidine or other chaotropic agents, followed by solvent extraction using phenol, phenol/chloroform and precipitation using isopropanol and ethanol (see Chomczynski & Sacchi , 1987, Anal Biochem 162 : 156-159) .
- RNA is Northern blotted with probes derived from the SEQ ID No 1 to identify transcript size of candidate human clones.
- Messenger RNA from the RNA pool is extracted using oligo-dT cellulose or poly-U sepharose chromatography and cDNA is constructed from this RNA using reverse transcriptase (Superscript) and DNA ligase.
- Double-stranded DNA is constructed and a directional cDNA library generated using lambda zap, lambda express, pcDNA, or other suitable vectors.
- the 3 ' untranslated region of the SPASIC clone is sub- cloned into a plasmid vector (Bluescript or similar) followed by cutting out the insert and isolating it on agarose gels.
- cRNA clones are labelled by in vi tro transcription with SP6, T3 or T7 polymerases and 32 P or DIG labelled nucleotides.
- the insert is radiolabelled by random prime or nick translation with 32 P or DIG-labelled nucleotides.
- the cDNA library is screened by moderate stringency hybridisation to 50-60°C 5 x SSC, using radiolabelled or other labelled DNA or cRNA probes derived from the 3 ' -UTR of the DNA/RNA sequence. Alternatively, other regions of the protein may be used. Resulting clones are plaque purified and their insert sized examined. Cross hybridisation of the clones follows with isolation of individual distinct clones. Clones that contain inserts that correspond approximately to the size of human mRNAs determined by Northern blotting are isolated. cRNA is generated from the selected clones and injected into Xenopus oocytes or COS (up to 50nls, lmg/ml) and using twin electrode voltage clamp studies, the expression of functional proton-gated channels investigated.
- Functionally active channel clones have their insert DNA sequenced and this DNA is recloned into a selectable shuttle vector (e.g. pcDNA neo- Invitrogen) to generate transiently or permanently transfected cell lines (COS cells, CHO cells, 293 cells etc.) expressing functional human ASIC protein clones. These cell lines may then be used with either 22 Na, 86 Rb, 45 Ca ion flux measurement, electrophysiology or Na or Ca-sensitive dye techniques to provide a high-throughput screen for channel agonist or antagonist candidate compounds.
- a selectable shuttle vector e.g. pcDNA neo- Invitrogen
- Example 4 PCR cloning of other mammalian SPASIC using sequence derived from the rat cDNA clone.
- Dorsal root ganglia and spinal cord are are isolated from available human or other mammalian tissue material.
- RNA is extracted from the isolated tissue by extraction in guanidine or other chaotropic agents, followed by solvent extraction using phenol, phenol/chloroform and precipitation using isopropanol and ethanol .
- Random primers and reverse transcriptase are used to generate cDNA from the extracted human RNA using either total or poly A+ RNA.
- Degenerate PCR primers derived from conserved regions of SEQ ID No-1 are used to amplify the cDNA using the polymerase chain reaction; e.g. using degenerate primer sequences SEQ ID No 4 and 5, 6 and 7 and 8 and 9.
- the products of the PCR reaction are separated on agarose gels and examined with products of the approximate predicted size being extracted and cloned into a pGemT vector.
- the clones are sequenced and the sequences examined for similarity with that of SEQ ID No 1.
- Candidate PCR fractions are used to screen a human cDNA DRG library as described in Example 2.
- Example 5 In vi tro expression of proton gated ASIC channels .
- Plasmids encoding SPASIC cDNA are cut with restriction enzymes Xhol and EcoRI.
- the SPASIC insert which comprises the protein encoding regions, is isolated from low melting agarose gel, and subcloned into pTracer-CMV and pgwl vectors respectively between EcoRI and Xhol restriction sites. The orientation of these constructs is checked by sequencing.
- Shuttle vectors eg. pTracer-CMV or pgwl containing SPASIC were purified from maxipreps . These vectors were used to express proton-gated channels by transfecting permanent cell line COS cells. Cultured COS cells from a 100 mm petri dish (80-90% confluent) were trypsinised and resuspended in 350 microlitres of ice cold HEBS buffer. 20-30 micrograms of plasmids of interest were dissolved with 150 microlitres of HEBS buffer, then mixed with the COS cell suspension in an electroporation cuvette and kept on ice to cool for 5 minutes.
- the electroporator (Invitrogen) was set up at 250 microFarad, and charged for 3 minutes at 330V, 25mA, and 25W.
- the cuvette was flicked to resuspend cells and electroporation effected.
- COS cells were seeded in low density in-30mm petri dish and cultured with 2ml MEM/10% FCS at 37°C for 2-3 days.
- the transfected cells were washed with buffer (in mM NaCl 146, KC1 5, CaCl 2 2, MgCl2 1, Glucose 10, HEPES 10 at various pHs) and using the whole cell configuration of the patch-clamp technique, currents evoked by perfusing with low pH buffer (pH 5) were measured at a holding potential of -60mV, with a 20 second perfusion duration of pH 5 buffer.
- buffer in mM NaCl 146, KC1 5, CaCl 2 2, MgCl2 1, Glucose 10, HEPES 10 at various pHs
- Example 6 Screening for ion channel modulatincr acrents
- Permanently or transiently transfected COS cell lines expressing SPASIC are loaded with C-14 guanidine (10 microcuries per ml) in multiwell plates for 1 hour at 37°C in DHEM growth medium containing 10% calf serum, washed in Hepes buffered saline (pH 7.4) 4 times, and rates of radioactivity released measured in the presence and absence of a low pH stimulus (pH 5.5 Hepes buffered saline) , with or without the addition of compounds that may show agonist, partial agonist or antagonist activity (Wood et al, 1989 J Neurochem 53: 1203-1211).
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Toxicology (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU41567/99A AU4156799A (en) | 1998-06-03 | 1999-06-03 | Ion channels |
EP99925184A EP1082425A2 (en) | 1998-06-03 | 1999-06-03 | Ion channels |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9811965.4A GB9811965D0 (en) | 1998-06-03 | 1998-06-03 | Ion channels |
GB9811965.4 | 1998-06-03 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO1999063081A2 true WO1999063081A2 (en) | 1999-12-09 |
WO1999063081A3 WO1999063081A3 (en) | 2000-01-27 |
Family
ID=10833161
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB1999/001743 WO1999063081A2 (en) | 1998-06-03 | 1999-06-03 | Ion channels |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP1082425A2 (en) |
AU (1) | AU4156799A (en) |
GB (1) | GB9811965D0 (en) |
WO (1) | WO1999063081A2 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000043514A2 (en) * | 1999-01-22 | 2000-07-27 | Millennium Pharmaceuticals, Inc. | Human acid sensing ion channel and uses thereof |
WO2001066125A1 (en) * | 2000-03-03 | 2001-09-13 | Ortho-Mcneil Pharmaceutical, Inc. | DNA ENCODING HUMAN ACID-SENSING ION CHANNEL BNaC4 (ASIC4) |
EP1908834A2 (en) | 2000-04-20 | 2008-04-09 | McGILL UNIVERSITY | Heteromultimeric ion channel receptor and uses thereof |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998035034A1 (en) * | 1997-02-11 | 1998-08-13 | Centre National De La Recherche Scientifique (Cnrs) | Mammal neuronal acid sensing cationic channel, cloning and applications thereof |
EP0875570A2 (en) * | 1997-05-01 | 1998-11-04 | Smithkline Beecham Plc | Neurodegenerative polypeptides HHPDZ65 |
-
1998
- 1998-06-03 GB GBGB9811965.4A patent/GB9811965D0/en not_active Ceased
-
1999
- 1999-06-03 WO PCT/GB1999/001743 patent/WO1999063081A2/en not_active Application Discontinuation
- 1999-06-03 EP EP99925184A patent/EP1082425A2/en not_active Withdrawn
- 1999-06-03 AU AU41567/99A patent/AU4156799A/en not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998035034A1 (en) * | 1997-02-11 | 1998-08-13 | Centre National De La Recherche Scientifique (Cnrs) | Mammal neuronal acid sensing cationic channel, cloning and applications thereof |
EP0875570A2 (en) * | 1997-05-01 | 1998-11-04 | Smithkline Beecham Plc | Neurodegenerative polypeptides HHPDZ65 |
Non-Patent Citations (1)
Title |
---|
RAINER WALDMANN ET AL.: "A proton-gated cation channel involved in acid-sensing" NATURE, vol. 386, no. 6621, 13 March 1997 (1997-03-13), pages 173-177, XP002068589 LONDON GB cited in the application * |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000043514A2 (en) * | 1999-01-22 | 2000-07-27 | Millennium Pharmaceuticals, Inc. | Human acid sensing ion channel and uses thereof |
WO2000043514A3 (en) * | 1999-01-22 | 2000-11-02 | Millennium Pharm Inc | Human acid sensing ion channel and uses thereof |
WO2001066125A1 (en) * | 2000-03-03 | 2001-09-13 | Ortho-Mcneil Pharmaceutical, Inc. | DNA ENCODING HUMAN ACID-SENSING ION CHANNEL BNaC4 (ASIC4) |
US6548270B1 (en) | 2000-03-03 | 2003-04-15 | Ortho-Mcneil Pharmaceutical, Inc. | DNA encoding human acid-sensing ion channel BNaC4 (ASIC4) |
EP1908834A2 (en) | 2000-04-20 | 2008-04-09 | McGILL UNIVERSITY | Heteromultimeric ion channel receptor and uses thereof |
Also Published As
Publication number | Publication date |
---|---|
GB9811965D0 (en) | 1998-07-29 |
WO1999063081A3 (en) | 2000-01-27 |
AU4156799A (en) | 1999-12-20 |
EP1082425A2 (en) | 2001-03-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP3798447B2 (en) | Cationic xenobiotics and / or transport proteins that transport drugs, DNA encoding the same, and uses thereof | |
JP2002514055A (en) | DNA encoding galanin GALR3 receptor and use thereof | |
US20050186627A1 (en) | Cloned peripheral nerve, tetrodotoxin-resistant sodium channel alpha-subunit | |
EP1007638B1 (en) | Kcnq potassium channels and methods of modulating same | |
US6441156B1 (en) | Calcium channel compositions and methods of use thereof | |
US6391561B1 (en) | Protein that enhances expression of potassium channels on cell surfaces and nucleic acids that encode the same | |
US5866372A (en) | Nucleic acids encoding lymphoid CD30 antigen | |
JP2001506481A (en) | Bradykinin B (1) DNA encoding receptor | |
EP1117782A2 (en) | Ion channels, in particular vanilloid receptor-like (vr-l) receptor | |
JP2005507246A (en) | Nogo receptor homologues and their use | |
CA2251262C (en) | Nucleic acid encoding a nervous tissue sodium channel | |
EP1082425A2 (en) | Ion channels | |
JPH06211898A (en) | Neural alpha-catenin | |
US20080234470A1 (en) | Kcnb: a novel potassium channel protein | |
JP2001501469A (en) | Nucleic acid molecules encoding tumor suppressor proteins and methods for isolating them | |
WO1999011784A1 (en) | Proton gated ion channel proteins | |
JPH11299489A (en) | Neutral amino acid transporter and gene coding for the same | |
AU2001250794A1 (en) | KCNB: a novel potassium channel protein | |
WO2000049048A1 (en) | Ndae1 - a new bicarbonate transporter | |
CA2271326A1 (en) | Dtf-a gene, diagnostic and therapeutic uses thereof | |
CA2284857A1 (en) | G protein coupled receptor a4 | |
WO2002070697A1 (en) | Mammalian nuclear receptor l67 and methods of use | |
WO2002033124A1 (en) | KChAP-MODULATOR OF POTASSIUM CHANNELS | |
WO2002024749A2 (en) | Isolated human transporter proteins, nucleic acid molecules encoding them, and uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1999925184 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09701747 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 1999925184 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1999925184 Country of ref document: EP |